Compare XPL & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPL | CVRX |
|---|---|---|
| Founded | 1984 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.7M | 81.3M |
| IPO Year | 2000 | 2021 |
| Metric | XPL | CVRX |
|---|---|---|
| Price | $0.66 | $2.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $1.20 | ★ $10.50 |
| AVG Volume (30 Days) | 223.5K | ★ 623.6K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $17.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $0.53 | $2.20 |
| 52 Week High | $0.98 | $11.30 |
| Indicator | XPL | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.29 | 43.25 |
| Support Level | $0.60 | $2.70 |
| Resistance Level | $0.80 | $3.24 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 57.47 | 64.21 |
Solitario Resources Corp is an exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. Its core mineral property assets are: the Florida Canyon zinc project in Peru, the Lik zinc project in Alaska, and the Golden Crest project in South Dakota. Additionally, Solitario holds an interest in the Chambara project in Peru and also has two early-stage projects, the Cat Creek project and the Bright Angel project in Colorado. The company is conducting mineral exploration on its Golden Crest project, the Cat Creek project, and the Bright Angel project on its own.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.